Xencor Cuts 2026 Cash Outlook by $20M–$30M After Royalties Dispute
Xencor cut its revenue outlook after Alexion asserted it owes no further U.S. royalties on Ultomiris, jeopardizing the $100–120M in royalties projected through 2028. The company lowered its 2026 cash forecast to $380M–$400M while maintaining a cash runway into mid-2028.
1. Royalty Dispute with Licensee
Xencor revealed that Alexion, under AstraZeneca ownership, notified the company it considers no additional royalties due on U.S. Ultomiris sales, contesting the terms of their XmAb Fc domain license.
2. Effect on Royalty Projections
Prior to the dispute, Xencor expected $100M–$120M in cumulative U.S. Ultomiris royalties through 2028. The disagreement has prompted a revision of royalty revenue expectations and removal of further U.S. royalty payments from the current outlook.
3. Revised Cash Forecast
With lower expected royalty inflows, Xencor trimmed its projected cash balance for year-end 2026 to $380M–$400M from $400M–$430M, while retaining a funding runway into mid-2028 to support ongoing operations and pipeline development.
4. Analyst View and Stock Momentum
William Blair labels the cash outlook revision slightly negative but points to 2026 clinical updates as the more impactful catalysts, keeping an Outperform rating. Technically, the stock trades 12.5% below its 20-day SMA with neutral RSI and bearish MACD, indicating mixed momentum.